Key result
Cardiomyocyte-specific expression of Q510E-SHP2 in mice enhanced contractile performance by augmenting intracellular Ca2+ cycling and increasing the number of power-generating sarcomeres.
In a mouse model of Noonan syndrome with multiple lentigines, the Q510E-SHP2 mutation causes cardiac hypercontractility early in disease progression by augmenting intracellular Ca2+ cycling and increasing power-generating sarcomeres.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for NSML hypercontractility mechanisms; leaves open human therapeutic translation.
Noonan syndrome with multiple lentigines (NSML) is primarily caused by mutations in the nonreceptor protein tyrosine phosphatase SHP2 and associated with congenital heart disease in the form of pulmonary valve stenosis and hypertrophic cardiomyopathy (HCM). Our goal was to elucidate the cellular mechanisms underlying the development of HCM caused by the Q510E mutation in SHP2. NSML patients carrying this mutation suffer from a particularly severe form of HCM. Drawing parallels to other, more common forms of HCM, we hypothesized that altered Ca(2+) homeostasis and/or sarcomeric mechanical properties play key roles in the pathomechanism. We used transgenic mice with cardiomyocyte-specific expression of Q510E-SHP2 starting before birth. Mice develop neonatal onset HCM with increased ejection fraction and fractional shortening at 4-6 wk of age. To assess Ca(2+) handling, isolated cardiomyocytes were loaded with fluo-4. Q510E-SHP2 expression increased Ca(2+) transient amplitudes during excitation-contraction coupling and increased sarcoplasmic reticulum Ca(2+) content concurrent with increased expression of sarco(endo)plasmic reticulum Ca(2+)-ATPase. In skinned cardiomyocyte preparations from Q510E-SHP2 mice, force-velocity relationships and power-load curves were shifted upward. The peak power-generating capacity was increased approximately twofold. Transmission electron microscopy revealed that the relative intracellular area occupied by sarcomeres was increased in Q510E-SHP2 cardiomyocytes. Triton X-100-based myofiber purification showed that Q510E-SHP2 increased the amount of sarcomeric proteins assembled into myofibers. In summary, Q510E-SHP2 expression leads to enhanced contractile performance early in disease progression by augmenting intracellular Ca(2+) cycling and increasing the number of power-generating sarcomeres. This gives important new insights into the cellular pathomechanisms of Q510E-SHP2-associated HCM.
No takes yet. Share an insight, caveat, or question.
Clay et al. (2015) studied Noonan syndrome with multiple lentigines (NSML) associated hypertrophic cardiomyopathy (HCM). Cardiomyocyte-specific expression of Q510E-SHP2 was evaluated on Ca(2+) handling, force-velocity relationships, and power-load curves. Cardiomyocyte-specific expression of Q510E-SHP2 in mice enhanced contractile performance by augmenting intracellular Ca2+ cycling and increasing the number of power-generating sarcomeres.
Synapse has enriched 10 related papers. Consider them for comparative context: